Even though rare, Phenylketonuria carries a tremendous healthcare burden and leads to severe intellectual disability in cases of a lack of proper treatment. Currently, the condition is majorly treated with modifications and restrictions in diet to limit the intake of phenylalanine.
As per the NORD, Phenylketonuria affects one in 13,500 to 19,000 newborns in the United States. As per DelveInsight’s epidemiological analysis, in the 7MM the prevalence of Phenylketonuria was 49,887 (the US, EU5, and Japan) in 2020, which is expected to increase further in the coming next decade.
To overcome the existing unmet therapeutics demand, several pharmaceutical companies in the Phenylketonuria Market such as PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceutical among others are developing novel pipeline therapies The launch of the emerging therapies in the coming years is expected to improve the treatment outlook and the life of the affected person.
For more details, visit: Key Companies in the Phenylketonuria Market